FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297486032> ?p ?o ?g. }

• W4297486032 endingPage "18" @default.
• W4297486032 startingPage "1" @default.
• W4297486032 abstract "Diffuse large B cell lymphoma (DLBCL) is the most common pathological subtype of non-Hodgkin lymphoma (NHL) and is the most common type of adult lymphoma. Due to the poor prognosis of relapsed/refractory DLBCL, new drug targets and therapeutic methods are urgently needed. We investigated the expression of programmed death ligand 1 (PD-L1) and 3-monooxygenase/tryptophan 5-monooxygenase activating protein zeta (14-3-3ζ or YWHAZ) in patients with DLBCL. The purpose was to verify the expression levels of YWHAZ and PD-L1 and their relationships with the prognosis of DLBCL and to lay a foundation for further study on the role of YWHAZ and PD-L1 in DLBCL. Immunohistochemistry was used in 140 patients with DLBCL to test protein expression levels of YWHAZ and PD-L1. All patients were followed up in the hospital or by telephone or via WeChat. The positive expression rate of YWHAZ was 62.14% (87/140). The expression was negatively correlated with the positive expression of BAD ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M1> <mi>r</mi> <mo>=</mo> <mo>−</mo> <mn>0.177</mn> </math> , <math xmlns=http://www.w3.org/1998/Math/MathML id=M2> <mi>P</mi> <mo>=</mo> <mn>0.036</mn> </math> ) and positively correlated with the positive expression of BCL-2 ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M3> <mi>r</mi> <mo>=</mo> <mn>0.180</mn> </math> , <math xmlns=http://www.w3.org/1998/Math/MathML id=M4> <mi>P</mi> <mo>=</mo> <mn>0.033</mn> </math> ). When the cut-off value for PD-L1 was established at 5%, 10%, 15%, and 20%, the corresponding positive expression rates of PD-L1 were 79.66% (94/118), 51.69% (61/118), 40.68% (48/118), and 36.44% (43/118). YWHAZ significantly affected the OS of DLBCL ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M5> <mi>P</mi> <mo>≤</mo> <mn>0.001</mn> </math> ). The prognosis of the patients was related to the positive expression of PD-L1 when the cut-off value of PD-L1 was 5% ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M6> <mi>P</mi> <mo>=</mo> <mn>0.033</mn> </math> ). However, positive expression of PD-L1 was not associated with the prognosis when the cut-off values of PD-L1 were 10% ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M7> <mi>P</mi> <mo>=</mo> <mn>0.404</mn> </math> ), 15% ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M8> <mi>P</mi> <mo>=</mo> <mn>0.208</mn> </math> ), and 20% ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M9> <mi>P</mi> <mo>=</mo> <mn>0.408</mn> </math> ). The positive expression of YWHAZ (hazard ratio 6.215; 95% confidence interval 3.214-12.017; <math xmlns=http://www.w3.org/1998/Math/MathML id=M10> <mi>P</mi> <mo><</mo> <mn>0.05</mn> </math> ) was an independent adverse prognostic factor for OS. YWHAZ may be an important oncogene in the occurrence and development of DLBCL and may be used as a therapeutic target. PD-L1 may be an oncogene or tumor suppressor gene in the occurrence and development of DLBCL. Different cut-off values of PD-L1 may affect the prognosis of DLBCL." @default.
• W4297486032 created "2022-09-29" @default.
• W4297486032 creator A5012698878 @default.
• W4297486032 creator A5020948704 @default.
• W4297486032 creator A5043954841 @default.
• W4297486032 creator A5044215334 @default.
• W4297486032 creator A5054866713 @default.
• W4297486032 creator A5062497413 @default.
• W4297486032 creator A5062996224 @default.
• W4297486032 creator A5084280684 @default.
• W4297486032 creator A5085859008 @default.
• W4297486032 creator A5087058736 @default.
• W4297486032 creator A5087227832 @default.
• W4297486032 date "2022-09-28" @default.
• W4297486032 modified "2023-10-14" @default.
• W4297486032 title "Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma" @default.
• W4297486032 cites W1135493307 @default.
• W4297486032 cites W2056557894 @default.
• W4297486032 cites W2068088132 @default.
• W4297486032 cites W2072646319 @default.
• W4297486032 cites W2078379872 @default.
• W4297486032 cites W2116956926 @default.
• W4297486032 cites W2123676782 @default.
• W4297486032 cites W2135707184 @default.
• W4297486032 cites W2147240268 @default.
• W4297486032 cites W2151456266 @default.
• W4297486032 cites W2386721966 @default.
• W4297486032 cites W2477255711 @default.
• W4297486032 cites W2787553551 @default.
• W4297486032 cites W2797197823 @default.
• W4297486032 cites W2806566001 @default.
• W4297486032 cites W2806906092 @default.
• W4297486032 cites W2809654973 @default.
• W4297486032 cites W2876878371 @default.
• W4297486032 cites W2889646458 @default.
• W4297486032 cites W2912655525 @default.
• W4297486032 cites W2920860763 @default.
• W4297486032 cites W2951060893 @default.
• W4297486032 cites W2954148306 @default.
• W4297486032 cites W2980823426 @default.
• W4297486032 cites W2986111828 @default.
• W4297486032 cites W2997643390 @default.
• W4297486032 cites W3004062854 @default.
• W4297486032 cites W3018010248 @default.
• W4297486032 cites W3129002360 @default.
• W4297486032 cites W3129156690 @default.
• W4297486032 cites W3165618429 @default.
• W4297486032 cites W3182283930 @default.
• W4297486032 cites W3205805755 @default.
• W4297486032 cites W3206256414 @default.
• W4297486032 cites W3214473842 @default.
• W4297486032 cites W4206724883 @default.
• W4297486032 cites W4213148554 @default.
• W4297486032 cites W4385986623 @default.
• W4297486032 doi "https://doi.org/10.1155/2022/5633096" @default.
• W4297486032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36213322" @default.
• W4297486032 hasPublicationYear "2022" @default.
• W4297486032 type Work @default.
• W4297486032 citedByCount "0" @default.
• W4297486032 crossrefType "journal-article" @default.
• W4297486032 hasAuthorship W4297486032A5012698878 @default.
• W4297486032 hasAuthorship W4297486032A5020948704 @default.
• W4297486032 hasAuthorship W4297486032A5043954841 @default.
• W4297486032 hasAuthorship W4297486032A5044215334 @default.
• W4297486032 hasAuthorship W4297486032A5054866713 @default.
• W4297486032 hasAuthorship W4297486032A5062497413 @default.
• W4297486032 hasAuthorship W4297486032A5062996224 @default.
• W4297486032 hasAuthorship W4297486032A5084280684 @default.
• W4297486032 hasAuthorship W4297486032A5085859008 @default.
• W4297486032 hasAuthorship W4297486032A5087058736 @default.
• W4297486032 hasAuthorship W4297486032A5087227832 @default.
• W4297486032 hasBestOaLocation W42974860321 @default.
• W4297486032 hasConcept C126322002 @default.
• W4297486032 hasConcept C204232928 @default.
• W4297486032 hasConcept C2778559949 @default.
• W4297486032 hasConcept C2779338263 @default.
• W4297486032 hasConcept C502942594 @default.
• W4297486032 hasConcept C71924100 @default.
• W4297486032 hasConceptScore W4297486032C126322002 @default.
• W4297486032 hasConceptScore W4297486032C204232928 @default.
• W4297486032 hasConceptScore W4297486032C2778559949 @default.
• W4297486032 hasConceptScore W4297486032C2779338263 @default.
• W4297486032 hasConceptScore W4297486032C502942594 @default.
• W4297486032 hasConceptScore W4297486032C71924100 @default.
• W4297486032 hasFunder F4320321001 @default.
• W4297486032 hasLocation W42974860321 @default.
• W4297486032 hasLocation W42974860322 @default.
• W4297486032 hasLocation W42974860323 @default.
• W4297486032 hasLocation W42974860324 @default.
• W4297486032 hasOpenAccess W4297486032 @default.
• W4297486032 hasPrimaryLocation W42974860321 @default.
• W4297486032 hasRelatedWork W1563073167 @default.
• W4297486032 hasRelatedWork W1964363570 @default.
• W4297486032 hasRelatedWork W2136143901 @default.
• W4297486032 hasRelatedWork W2391494730 @default.
• W4297486032 hasRelatedWork W2896388442 @default.
• W4297486032 hasRelatedWork W2980891769 @default.
• W4297486032 hasRelatedWork W3001698141 @default.

• next